New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV

TARRYTOWN, N.Y. and PARIS , Sept. 21, 2021 /PRNewswire/ —  More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents and adults Results provide insight into the clinical and


Get every new post delivered right to your inbox.

Original Source